HHS and DoD jointly announced: – A $1.6 billion agreement with Novavax to demonstrate commercial-scale manufacturing of the company’s COVID-19 investigational vaccine, NVX-CoV2373. The agreement expands upon a June agreement for Novavax to provide 10 million doses for use in Phase 2/3 clinical trials. The July 7 agreement is expected to provide the federal government with 100 million doses of the investigational vaccine.- A $450 million agreement with Regeneron to demonstrate commercial-scale manufacturing of the company’s investigational therapeutic treatment, REGN-COV2. The agreement is expected to produce between 70,000 and 300,000 treatment doses expected by fall. Clinical trials for the investigational therapeutic are currently underway.